Chapter-4

THE GUT MICROBIOME AND ITS ROLE IN HUMAN HEALTH

[1]Manish Kumar, [2]Dr. Suchandra Gupta, [3]Dr.Manisha Khandait

[1]Department of Medical Laboratory Technology and Biochemistry, School of Allied Health Sciences, SGT University, Gurugram, Haryana, India.
[2]Assistant Professor, Department of Medical Laboratory Technology and Biochemistry, School of Allied Health Sciences, SGT University, Gurugram, Haryana, India.
[3]Professor, Department of Microbiology, Faculty of Medicine and Health Sciences, SGT University, Gurugram, Haryana, India.


LEARNING OBJECTIVES

1. Describe the composition and normal physiology of the vaginal microbiome, including the predominant role of Lactobacillus species in maintaining vaginal homeostasis and reproductive health.
2. Explain the major functions of the vaginal microbiome, including regulation of vaginal pH, prevention of pathogen colonization, maintenance of epithelial barrier integrity, immune modulation, metabolic activity, and support of reproductive health.
3. Identify the intrinsic and extrinsic factors that influence vaginal microbiome composition, such as hormonal changes, menstrual cycle, sexual activity, antibiotic exposure, immune status, ethnicity, lifestyle, and intimate hygiene practices.
4. Discuss the mechanisms and clinical consequences of vaginal dysbiosis, including its association with bacterial vaginosis, vulvovaginal candidiasis, sexually transmitted infections, pelvic inflammatory disease, adverse pregnancy outcomes, polycystic ovary syndrome, and endometriosis.
5. Compare the conventional and molecular diagnostic approaches used for evaluating the vaginal microbiome, including Amsel's criteria, Nugent scoring, Gram staining, PCR-based assays, 16S rRNA gene sequencing, and whole-genome sequencing.
6. Evaluate the impact of intimate hygiene practices and lifestyle behaviors on vaginal microbial balance, and recognize evidence-based recommendations for maintaining a healthy vaginal ecosystem.
7. Describe current preventive and therapeutic strategies for restoring vaginal microbial homeostasis, including probiotics, antimicrobial therapy, vaginal microbiota transplantation, and appropriate hygiene and lifestyle interventions.

4.1 INTRODUCTION

The human gastrointestinal tract harbours a rich and diverse population of microorganisms, which is commonly referred to as the gut microbiome. [1] The term microbiome combines “micro” and “biome”, describing a microbial community living in a well-defined habitat characterised by specific physical and chemical conditions that serve as their stage of interaction. [2] The gut microbiome is the complete system, which includes the microorganisms, their genomes, metabolic products and the interaction with host and surrounding environmental content, whereas the term microbiota refers to the community of microorganisms in the specific environment.[3] The human gut flora plays an important role in gastrointestinal and overall human health. [4] The human gut microbiome is primarily composed of four bacterial phyla: Firmicutes, Bacteroidetes, *Proteobacteria*, and *Actinobacteria*. Among them, the majority of the gut is composed of Firmicutes and Bacteroidetes. [5] An adult human gut consists of approximately 10^{13}-10^{14} microbes that tend to change with age. [6] Actinobacteria represent the most prevalent taxa after the

nutritional shift, whereas older people above the age of 70 years have a significant rise in proteobacteria, and a balanced microbial composition is observed in healthy hosts. [7] The microbial diversity in human gut microbiome is begins at birth and evolves throughout the life. It is widely assumed that a healthy human foetus is developed in a sterile bacteria free environment. [8] Upon delivery, the neonates come into contact with many microbes, most of which are provided by the mother during and after its journey to the birth canal, which is rich in bacterial taxa. [9] As many modern delivery processes like C-section changes the mode of delivery which limit the vaginal exposure leading to the alteration in the microbiome. [10]



The C-section microbiome was enriched in MetaOTUs such as *Haemophilus parainfluenzae/H.aegyptius/H. influenzae/H. haemolyticus, Staphylococcus saprophyticus/S. lugdunensis/S. aureus, Streptococcus australis, Enterobacter hormaechei/E. cancerogenus and Veillonella dispar/V. parvula* whereas the gut microbiome of vaginally delivered newborn were enriched with genera *Bacteroides, Bifidobacterium, Parabacteroides, Escherichia/Shigella*. [11] In parallel, the infants who were breastfed tend to develop beneficial taxa such as Bifidobacterium longum, lactobacillus johnsonil/gasseri, and L. paracasel/casl. Conversely, formula-fed tend to develop potentially pathogenic microorganism such as Closteidium difficile, Citrobacter, Enterobacter cloacae, and Bilophila wadsworthia. [12,13] During childhood, the introduction of table foods initiates a major shift in the gut microbiome, which promotes the prevalence of Bacteroidetes and Firmicutes, leading to a more stable and organised microbial community that mirrors an adult gut.[14] During adolescence, the gut microbiota composition tends to shift due to hormonal and other puberty changes.[15]

The microbiota achieves more stability and differentiated state with Firmicutes, Bacteroidetes, and Actinobacteria forming the dominant phyla. [16,17] Although the gut microbiome still shows differences across individuals influenced by factors such as dietary habits and geographical location. As the ageing continues, the gut microbiota experiences significant alterations resulting in more variability and lower diversity compared to adulthood. These alterations are shaped by several factors such as aging process, dietary pattern, hormonal changes and geographical factors. [18]



Figure: 4.1 Human Gut Microbiome Development over a lifetime

4.2 FUNCTIONAL ROLE OF THE GUT MICROBIOME

The gut microbiome functions as a highly active metabolic and immunological organ that contributes significantly to human health. Beyond simply residing in the gastrointestinal tract, intestinal microorganisms participate in the digestion of complex dietary compounds, synthesis of essential nutrients, regulation of host metabolism, and maintenance of intestinal and systemic homeostasis. Through the production of

bioactive metabolites and continuous communication with host tissues, the gut microbiome influences energy balance, immune responses, endocrine signalling, and disease susceptibility. Among its many physiological functions, microbial metabolism, vitamin biosynthesis, and bile acid transformation represent some of the most important mechanisms through which the gut microbiome supports normal human physiology.

4.2.1 Metabolic Functions

One of the primary roles of the gut microbiome is to metabolise dietary compounds that cannot be digested by human enzymes. Complex carbohydrates, resistant starches, dietary fibres, and certain proteins reach the colon largely undigested, where they serve as substrates for microbial fermentation. This process produces numerous bioactive metabolites that influence intestinal physiology, host metabolism, and immune regulation.

A. Short-Chain Fatty Acid Production: Short-chain fatty acids (SCFAs) are among the most important metabolites produced by the gut microbiota. They are generated through the anaerobic fermentation of dietary fibres, resistant starches, and selected amino acids by beneficial intestinal bacteria. The three major SCFAs acetate, propionate, and butyrate account for the majority of microbial fermentation products in the colon and are influenced by dietary composition, microbial diversity, antibiotic exposure, and other environmental factors. [19,20] SCFAs perform numerous physiological functions that extend well beyond the gastrointestinal tract. They serve as signalling molecules by activating G protein-coupled receptors (GPCRs), including GPR41, GPR43, and GPR109A, thereby regulating epithelial integrity, immune responses, and systemic metabolism. [20] These metabolites also promote the production of anti-inflammatory cytokines while suppressing excessive inflammatory signalling, contributing to immune homeostasis. Among the SCFAs, butyrate is considered the most beneficial for intestinal health. It provides nearly 70% of the energy requirements of colonocytes and supports epithelial renewal by enhancing the expression of tight junction proteins and stimulating mucin secretion, thereby strengthening the intestinal barrier. [20,21] In addition, butyrate functions as a histone deacetylase (HDAC) inhibitor, influencing gene expression involved in immune regulation and inflammation. Propionate is transported to the liver through the portal circulation, where it contributes to gluconeogenesis and helps regulate cholesterol metabolism. Acetate, the most abundant SCFA, enters the systemic circulation and serves as a substrate for lipid synthesis and energy metabolism in peripheral tissues. [19] Together, these microbial metabolites establish an essential link between dietary fibre intake, intestinal health, and whole-body metabolic regulation.

B. Vitamin Synthesis: In addition to metabolite production, the gut microbiome acts as an important endogenous source of several essential vitamins. Numerous intestinal bacteria synthesise vitamin K and a variety of B-complex vitamins, including biotin (vitamin B7), folate (vitamin B9), cobalamin (vitamin B12), riboflavin (vitamin B2), thiamine (vitamin B1), pyridoxine (vitamin B6), niacin (vitamin B3), and pantothenic acid (vitamin B5). These vitamins serve as indispensable cofactors in metabolic reactions, cellular growth, immune regulation, and neurological function. [22] Metagenomic studies have demonstrated that the gut microbiome contains numerous clustered orthologous groups (COGs) involved in vitamin biosynthesis pathways. These include genes responsible for the synthesis of deoxyxylulose-5-phosphate, an important precursor for thiamine and pyridoxal biosynthesis. [23]

Among the vitamins produced by intestinal microbes, riboflavin and niacin are considered particularly abundant. Microbially synthesised riboflavin (vitamin B2) participates in the activation of mucosal-associated invariant T (MAIT) cells, thereby contributing to antimicrobial immune responses. Pantothenic acid (vitamin B5) supports cellular metabolism and coenzyme A synthesis, whereas folate (vitamin B9) plays an important role in DNA synthesis, methylation reactions, and maintenance of regulatory T-cell (Treg) stability, promoting immune tolerance. [24,25] Vitamin B12 (cobalamin) is essential for DNA synthesis, erythropoiesis, and energy metabolism. Alterations in microbial vitamin B12 metabolism have also been associated with colorectal carcinogenesis in some studies. Similarly, microbial production of niacin (vitamin B3) activates the GPR109A receptor

following transport through the SLC5A8 transporter, contributing to anti-inflammatory signalling and maintenance of intestinal epithelial function. [26] Collectively, these microbially synthesised vitamins constitute an important component of the microbiota–metabolite–immunity axis, linking microbial metabolism with immune regulation, epithelial integrity, and protection against chronic inflammatory diseases.

C. Bile Acid Metabolism: The gut microbiome also plays a central role in bile acid metabolism, thereby influencing lipid digestion, glucose homeostasis, energy expenditure, and immune regulation. Primary bile acids, including cholic acid (CA) and chenodeoxycholic acid (CDCA), are synthesised from cholesterol in the liver before being conjugated and secreted into the small intestine to facilitate lipid digestion. [27] Following their release into the intestine, these primary bile acids undergo extensive microbial transformation. The first step involves bile salt hydrolase (BSH)-mediated deconjugation, an enzymatic reaction performed by several gut bacterial species that removes glycine or taurine conjugates from bile acids. [28] This process creates substrates for further microbial modifications. Subsequently, specialised anaerobic bacteria, particularly Clostridium scindens, catalyse 7α-dehydroxylation through enzymes encoded by the bai operon, converting primary bile acids into biologically active secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid (LCA). [29] These secondary bile acids function not only as digestive molecules but also as important endocrine signalling compounds. They activate nuclear and membrane receptors, including the Farnesoid X Receptor (FXR) and the Takeda G-protein-coupled receptor 5 (TGR5), which regulate cholesterol metabolism, glucose homeostasis, insulin sensitivity, lipid metabolism, energy expenditure, and inflammatory responses. [28] Furthermore, microbial-derived bile acids influence adaptive immunity by modulating T-cell differentiation and promoting immune tolerance, highlighting the extensive interaction between microbial metabolism and host physiology. Overall, microbial bile acid transformation represents one of the most important examples of host–microbiome cooperation, demonstrating how intestinal microorganisms regulate metabolic and immune functions far beyond the gastrointestinal tract.

4.2.2 Immune System Modulation

The gut microbiota plays a crucial role in immune modulation, influencing both local and systemic immune responses. Studies have revealed that the gut microbiota can affect multiple functions in the human body, including the immune system, through factors that affect its modulation (altered responses to maintain immune balance), maturation, and functioning. [30]

A. Immune development: Microbial exposure beginning in utero and accelerating at birth is indispensable for the functional maturation of the host immune system. [31] During early life progression, constant monitoring of microbial-associated molecular patterns (MAMPs) occurs via gut-lymphoid tissues, thereby promoting the differentiation of macrophages and innate lymphoid populations. [32,33] These interactions shape the host's immunological trajectory via refining local tissue circuits throughout sensitive developmental windows. [34]

B. Regulatory cells and immune tolerance: The gut microbiota stimulates immune tolerance via promoting the differentiation of FoxP3+ regulatory T cells (Treg), precisely the RORγt+ peripheral Treg population. [35] Through the utilisation of cell surface polysaccharides and secondary bile acid, some gut commensal species resembling *Bacteroides fragilis* and *Bifidobacterium* stimulate the tolerogenic dendritic cells, supporting Treg proliferation and IL-10 secretion. [36,37] These cells are essential for preventing excessive immune activation against beneficial commensal microorganisms and harmless dietary antigens. [38]

C. Inflammation Regulation: The microbiome regulates inflammatory pathways through bioactive metabolites, primarily short-chain fatty acids (SCFAs) produced via saccharolytic fermentation. SCFAs such as butyrate act as histone deacetylase (HDAC) inhibitors, repressing NF-κB signalling and down-regulating pro-inflammatory cytokines like TNF-α and IL-6. [39] By signalling through G-protein coupled receptors, these metabolites reinforce epithelial barrier integrity and preserve systemic homeostasis by balancing pro-inflammatory Th17 and anti-inflammatory Treg activities. [40]

4.2.3 Barrier function and gut integrity

The intestinal barrier is a multi-layered defensive system that maintains physiological homeostasis

through essential, bidirectional interactions between the host epithelium and the resident gut microbiota. [41]

A. Tight Junctions and Epithelial Integrity: Commensal microbes regulate the expression and assembly of tight junction (TJ) proteins, such as occludin, claudins, and zonula occludens (ZO-1), which seal paracellular pathways. By fortifying these cellular anchors, the microbiota preserves epithelial integrity and prevents the systemic translocation of luminal pathogens and toxins into the host's internal milieu. [42] Dysregulation of TJ proteins can lead to excessive permeability of the intestinal barrier. Bacteria can change the expression and distribution of TJ proteins and thus affect intestinal permeability. For example, some pathogenic strains of *Escherichia coli*, including *the E. coli O157:H7 strain, which causes bloody diarrhoea*, produce toxins such as Shiga toxins (STx). The latter suppress protein biosynthesis and contribute to the development of hemolytic uremic syndrome, which is a life-threatening complication. [43]

B. Mucus Layer Maintenance: The mucous layer separates gut microorganisms from the epithelium. Mucus consists of 95% water, and the rest is mucin proteins. [44] The microbiota also stimulates goblet cells to produce and maintain the mucus layer, which is primarily composed of the gel-forming mucin MUC2**.** [45] Specific species, such as *Bifidobacterium*, secrete metabolites like acetate and GABA to signal mucin synthesis and rapid expulsion, creating a biochemical shield that segregates the epithelium from direct bacterial contact. [46] In diseased conditions, the gut microbiota can modulate the properties of mucus. In particular, bacteria can affect the glycan profile of mucus via the activation of glycosyltransferases. These enzymes create a selective habitat for the gut microbial community because only certain microorganisms can bind to the mucin glycans in mucus. In this way, the gut microbiota can change the composition and properties of mucus, which undoubtedly affect the integrity and permeability of the intestinal barrier. [47]

C. Dysbiosis and Leaky Gut: Dysbiosis, the loss of microbial homeostasis, triggers the enzymatic degradation of the mucus barrier and the disruption of TJ complexes, causing increased intestinal permeability or "leaky gut".[48] This compromise facilitates the translocation of pro-inflammatory lipopolysaccharides (LPS) and other microbial antigens, driving chronic inflammation and elevating the risk for systemic pathologies, including metabolic and cardiovascular diseases. [42]

4.2.4 Microbiota gut-brain axis

The microbiota–gut–brain axis (MGBA) represents a complex, bidirectional communication system that integrates the central nervous system (CNS) and the enteric nervous system (ENS) with the gastrointestinal microbiota to regulate homeostatic and behavioural functions. [49] Communication along this axis is mediated via different yet overlapping neural, endocrine, and immune mechanisms.




Figure: 4.2 Microbiota Gut Brain Axis

The vagus nerve is indeed the primary neural conduit, operating its afferent fibres to communicate via signals from specialised gut neuroepithelial cells to brainstem nuclei and limbic regions that process emotions. [49,50] The gut microbiota reaches the endocrine system via the HPA axis, where it shapes stress responsiveness and modulates glucocorticoid production. [51] Within the immune pathway,

pattern-recognition receptors on gut-resident immune cells are stimulated by microbial molecular patterns, promoting the release of pro-inflammatory cytokines, including IL-6 and TNF-α, which can modulate microglial development and blood-brain barrier stability. [52] Besides, the microbiota plays a crucial role in neurochemical homeostasis; for instance, Bifidobacterium and Lactobacillus species modulate inhibitory neurotransmission, certain Clostridium strains are precursors of dopamine, and native bacteria regulate the synthesis of approx. 95% of the body's serotonin (5-HT) is mediated by enterochromaffin cell. [49,53]

Gut microbes mediate biochemical crosstalk by means of metabolites, remarkably SCFAs such as butyrate, which turn histone deacetylase (HDAC) inhibitors and G protein-coupled receptor ligands to affect gene expression associated with neuroplasticity. [54] Moreover, the kynurenine pathway of tryptophan metabolism, alongside neuroactive compounds including SCAs, acts as a critical signalling modulator. This unified axis supervises neurodevelopment, mood, and cognitive health, and its perturbation is linked to the aetiology of psychiatric and neurodegenerative conditions.

4.2.5 Microbiota-Gut-Lung axis

The microbiota-gut-lung axis denotes a two-way communication between gastrointestinal microbiota and respiratory system via immunological and metabolic pathways. This axis derives through systemic circulation, immune signalling, and microbial metabolites, chiefly SCFAs, which adjust distal pulmonary immune reactions and uphold mucosal homeostasi. [54-56] Gut metabolites shape pulmonary processes through haematopoiesis, augmenting Treg cell proliferation and fine-tuning cytokine production, thereby affecting pulmonary immunotolerance and inflammation. [57]

In addition, epithelial stability and alveolar macrophage activity are induced by microbial components and metabolites that translocate via the lungs' systemic circulation. Dysbiosis perturbs this equilibrium, driving hyperimmune activation and immune dysregulation that facilitate the pathogenesis of respiratory diseases, including asthma, chronic obstructive pulmonary disease, infections, and lung cancer. [58,59] Early-life microbial colonisation shapes immune maturation, and alterations in the microbiome are associated with increased susceptibility to paediatric respiratory conditions, including asthma and infections. [60,61] In adulthood, this axis is further adjusted via environmental factors, diet, and antibiotic exposure, which govern disease progression and severity. Therapeutically, microbiome-aimed strategies, including probiotics, prebiotics, and dietary variation, act to rebalance gut microbes and enhance pulmonary outcomes through upregulating the anti-inflammatory cascade and immunological robustness. Collectively, this axis signifies the integrative system that links gut microbial ecology to respiratory health and disease.



Figure: 4.3 Microbiota Gut Lung Axis

4.3 GUT MICROBIOME IN HUMAN HEALTH

The gut microbiome is fundamental to maintaining human health by supporting metabolic processes, regulating immune function, preserving intestinal barrier integrity, and facilitating communication between different organ systems. A balanced microbial ecosystem contributes to physiological stability, whereas disturbances in microbial composition, known as dysbiosis, are increasingly associated with a wide range of chronic diseases. Beyond aiding digestion, gut microorganisms produce essential

metabolites, interact with host cells, and influence numerous biological pathways that are critical for maintaining overall health and preventing disease.

4.3.1 Homeostasis and Symbiosis

The healthy gut microbiome exists in a dynamic state of homeostasis, where diverse microbial communities coexist with the host in a mutually beneficial relationship known as symbiosis. Rather than functioning independently, humans and their resident microorganisms form a biological unit often described as a holobiont, in which both partners contribute to normal physiological functions. This balanced microbial ecosystem supports digestion, nutrient metabolism, immune regulation, and protection against invading pathogens through continuous interactions between microbial metabolites and host tissues. [62,63]

One of the primary functions of the gut microbiome is maintaining immune homeostasis. Commensal microorganisms interact with pattern recognition receptors (PRRs) expressed on intestinal epithelial and immune cells, promoting immune tolerance while preserving the ability to respond effectively to harmful pathogens. These interactions stimulate the expansion of regulatory T (Treg) cells, suppress excessive inflammatory responses, and promote the production of antimicrobial peptides that limit the growth of pathogenic microorganisms. [37] At the same time, beneficial microbes compete with invading pathogens for nutrients and attachment sites, providing a natural barrier against infection. The resilience of this microbial ecosystem depends on high microbial diversity, functional redundancy, and balanced metabolic activity.

A diverse microbiome enables the gut to adapt to changes in diet, environmental exposures, and physiological stress while maintaining essential metabolic and immunological functions. Conversely, disruption of microbial diversity leads to dysbiosis, a condition characterized by the depletion of beneficial microorganisms and the overgrowth of opportunistic or pathogenic species. Dysbiosis weakens intestinal barrier integrity, promotes chronic low-grade inflammation, and alters microbial metabolite production. These changes increase susceptibility to numerous disorders, including inflammatory bowel disease, obesity, type 2 diabetes, cardiovascular disease, autoimmune disorders, and several gastrointestinal conditions. [64] Therefore, preserving microbial homeostasis is essential for maintaining long-term health and preventing disease.

4.3.2 Role in Nutrition and Energy Balance

The gut microbiome plays a central role in nutrient metabolism and energy homeostasis by metabolizing dietary components that cannot be digested by human enzymes. Complex carbohydrates, resistant starches, dietary fibres, and various polysaccharides reach the colon largely intact, where they are fermented by specialized gut microorganisms into biologically active metabolites.[65] This microbial fermentation substantially expands the host's metabolic capacity and enables efficient utilization of otherwise indigestible nutrients. Among the most important microbial metabolites are the short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. These compounds serve multiple physiological functions. Butyrate is the preferred energy source for colonocytes, supporting epithelial integrity and maintaining intestinal barrier function. Acetate and propionate enter the systemic circulation, where they participate in glucose metabolism, lipid synthesis, and hepatic gluconeogenesis.

In addition, SCFAs function as signalling molecules by activating G-protein-coupled receptors, particularly GPR41 and GPR43, thereby regulating appetite, insulin sensitivity, energy expenditure, and inflammatory responses. [65,66] Gut microorganisms also influence whole-body energy balance by regulating hormones involved in appetite and satiety. SCFAs stimulate enteroendocrine cells to release glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), hormones that promote satiety, delay gastric emptying, and improve glucose homeostasis. Furthermore, certain microbial communities regulate lipid storage by suppressing fasting-induced adipose factor (FIAF), resulting in increased lipoprotein lipase activity and enhanced triglyceride deposition in adipose tissue. These interactions demonstrate that the gut microbiome acts as an important metabolic organ that directly influences host energy utilization. Alterations in microbial composition have been strongly associated with metabolic disorders. Several studies have linked changes in the relative

abundance of Firmicutes, Bacteroidetes, and Proteobacteria with increased energy extraction from the diet, metabolic endotoxemia, obesity, and insulin resistance. Conversely, reduced microbial diversity and diminished functional gene content have been associated with malnutrition, impaired nutrient absorption, and metabolic syndrome. [67] Collectively, these findings emphasize that maintaining a diverse and balanced gut microbiome is essential for optimal nutritional status, efficient energy metabolism, and long-term metabolic health.

4.4 FACTORS INFLUENCING THE GUT MICROBIOME

The composition and function of the gut microbiome are highly dynamic and continuously shaped by a combination of dietary habits, medication use, lifestyle choices, environmental exposures, and host genetics. These factors influence not only the diversity and abundance of microbial communities but also their metabolic activities and interactions with the host. While some factors promote a healthy and resilient microbiome, others may disturb microbial balance, resulting in dysbiosis and increasing the risk of chronic diseases. Understanding these influences is essential for developing effective strategies to maintain or restore gut microbial homeostasis.

4.4.1 Diet

Diet is considered the most important modifiable factor influencing the gut microbiome. The nutrients consumed daily directly determine which microbial populations thrive in the gastrointestinal tract, thereby affecting microbial diversity, metabolic activity, and overall gut health.[68] Long-term dietary habits have a profound impact on microbial composition, making nutrition one of the most effective approaches for modulating the gut microbiome. Plant-based diets rich in dietary fibre, microbiota-accessible carbohydrates (MACs), and polyphenols such as the Mediterranean diet promote a diverse and stable microbial ecosystem. These dietary patterns encourage the growth of beneficial saccharolytic bacteria, including *Bifidobacterium*, *Lactobacillus*, *Prevotella*, *Ruminococcus*, *Eubacterium*, *Faecalibacterium prausnitzii*, and *Roseburia*.[69,70] These microorganisms ferment complex carbohydrates that escape digestion in the small intestine, producing short-chain fatty acids (SCFAs), particularly butyrate, acetate, and propionate. SCFAs serve as an important energy source for colonocytes, strengthen intestinal barrier function, regulate immune responses, and reduce intestinal inflammation. [66] The typical Western diet, which is rich in saturated fats, refined sugars, and highly processed foods, has been consistently associated with reduced microbial diversity and gut dysbiosis. Such dietary patterns favour the growth of bile-tolerant and pro-inflammatory microorganisms, including *Bilophila wadsworthia*, while reducing populations of beneficial fibre-fermenting bacteria. [71]

High consumption of animal proteins also shifts microbial metabolism toward proteolytic fermentation, resulting in the production of potentially harmful metabolites such as ammonia, hydrogen sulphide, and *p*-cresol, which may damage the intestinal epithelium and promote chronic inflammation. [72,73] Dietary polyphenols, naturally present in fruits, vegetables, tea, cocoa, and whole grains, also exhibit prebiotic-like properties. These bioactive compounds selectively stimulate the growth of beneficial microorganisms, particularly *Akkermansia muciniphila*, which has been associated with improved intestinal barrier integrity, metabolic health, and reduced inflammation. [74] Consequently, long-term dietary patterns play a central role in determining gut microbial composition, and diet-induced dysbiosis has been implicated in the development of obesity, type 2 diabetes, cardiovascular diseases, inflammatory bowel disease, and neuropsychiatric disorders. [75]

4.4.2 Antibiotics and Medications

Medications are another major determinant of gut microbiome composition. Among all pharmaceutical agents, antibiotics have the greatest impact because they eliminate both pathogenic and beneficial microorganisms, leading to substantial alterations in microbial diversity and ecological balance. [76,77] Although antibiotics remain indispensable for treating bacterial infections, their widespread and often inappropriate use has contributed significantly to microbial dysbiosis and antimicrobial resistance. Even short courses of antibiotics can rapidly reduce microbial diversity and disturb the normal

balance of gut microorganisms. This disruption increases susceptibility to opportunistic pathogens, particularly *Clostridioides difficile*, which may proliferate after beneficial microbial populations are depleted. [78] Moreover, repeated or prolonged antibiotic exposure can produce long-lasting changes in the gut microbiome, with some studies suggesting that microbial recovery may take several years and may never return completely to its original state. [79] Beyond antibiotics, several commonly prescribed medications also influence gut microbial composition. Proton pump inhibitors (PPIs) alter gastric acidity, allowing microorganisms that are normally eliminated in the stomach to colonize the intestine. Non-steroidal anti-inflammatory drugs (NSAIDs) can affect intestinal permeability and microbial balance, while antidiabetic medications such as metformin modify microbial populations in ways that may contribute to their therapeutic effects. [80] Drug–microbiome interactions are increasingly recognized as an important factor influencing drug metabolism, bioavailability, efficacy, and toxicity. Furthermore, prolonged medication use may promote the spread of antimicrobial resistance genes within the gut microbiome through horizontal gene transfer, contributing to expansion of the gut resistome and alterations in host metabolism. [81]

4.4.3 Lifestyle Factors

Lifestyle choices exert significant effects on the diversity, stability, and metabolic activity of the gut microbiome. Factors such as psychological stress, physical activity, sleep quality, and circadian rhythm collectively influence microbial ecology and host health. Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to sustained cortisol release that alters gut physiology and microbial composition. [82] Stress-induced hormonal changes can impair intestinal barrier function, increase gut permeability, and promote inflammatory responses, thereby contributing to microbial dysbiosis. [83] Persistent stress has also been associated with reduced microbial diversity and impaired production of beneficial microbial metabolites. Regular physical activity positively influences the gut microbiome by increasing microbial diversity and enriching beneficial bacterial genera such as *Lactobacillus* and *Bifidobacterium*. [84] Exercise also enhances the production of SCFAs, improves metabolic efficiency, strengthens immune regulation, and supports intestinal barrier integrity. These beneficial effects partly explain the reduced risk of metabolic and inflammatory diseases observed in physically active individuals. Adequate sleep and healthy circadian rhythms are equally important for maintaining microbial homeostasis. Disruption of normal sleep patterns, including shift work and chronic sleep deprivation, alters microbial oscillations and weakens communication between the host and intestinal microorganisms. [85] Such disturbances have been associated with metabolic dysfunction, obesity, insulin resistance, chronic inflammation, and neuropsychiatric disorders. Therefore, maintaining a healthy lifestyle through regular exercise, stress management, and sufficient sleep contributes significantly to preserving a balanced and resilient gut microbiome. [82]

4.4.4 Environmental and Genetic Factors

Both environmental exposures and host genetic factors contribute substantially to shaping the gut microbiome throughout life. Their combined influence determines microbial diversity, ecological stability, and functional capacity, particularly during the critical periods of early microbial colonization. Environmental influences begin immediately after birth and continue throughout life. Geographic location, sanitation, dietary practices, socioeconomic conditions, and lifestyle habits all affect microbial exposure and colonization patterns. [86,87] Individuals living in different regions often exhibit distinct gut microbial profiles because of variations in diet, climate, environmental microorganisms, and cultural practices. Family structure also contributes to microbial transmission, with older siblings, household members, and close interpersonal contact facilitating the exchange and diversification of microbial communities. [88] Early-life exposure to antibiotics represents one of the strongest environmental influences on microbiome development. Antibiotic administration during infancy can disrupt normal microbial colonization, reduce microbial diversity, and produce long-lasting alterations that increase susceptibility to allergic, metabolic, and autoimmune diseases later in life. [89] Longitudinal studies indicate that environmental exposures during infancy and childhood have lasting effects on microbial development and may influence health outcomes well into adulthood. [90] Host

genetics also shape the gut microbiome by regulating mucosal immunity, epithelial barrier function, mucus production, and metabolic pathways that determine which microorganisms can successfully colonize the gastrointestinal tract. Genetic variation influences immune recognition, antimicrobial peptide production, and nutrient availability within the gut, thereby contributing to the establishment of a stable and resilient microbial ecosystem. Overall, the gut microbiome develops through continuous interactions between environmental exposures and host genetic factors. Together, these influences determine microbial diversity, metabolic function, immune maturation, and long-term health, emphasizing the importance of both inherited and modifiable factors in maintaining a healthy gut microbiome.

4.5 METHODS FOR STUDYING THE GUT MICROBIOME

Understanding the composition and function of the gut microbiome requires a combination of microbiological, molecular, and computational approaches. Over the past two decades, advances in sequencing technologies and bioinformatics have transformed microbiome research, allowing scientists to investigate not only which microorganisms are present but also what they do and how they interact with the host. While traditional culture-based methods remain valuable for studying microbial physiology and antimicrobial susceptibility, modern molecular and computational techniques provide comprehensive insights into microbial diversity, functional potential, and host–microbe interactions. Integrating these complementary methods has greatly improved our understanding of the gut microbiome in both health and disease.

4.5.1 Culture-Based Techniques

Culture-based microbiological methods represent the earliest and most fundamental approaches used to investigate the gut microbiome. These techniques involve growing microorganisms under controlled laboratory conditions using selective, differential, aerobic, or anaerobic culture media to isolate individual microbial species for further study. Once isolated, microorganisms can be identified through colony morphology, biochemical tests, microscopic examination, and phenotypic characterization. These methods provide valuable information regarding microbial physiology, metabolic activities, antimicrobial susceptibility, and interactions with the host. Enrichment culture techniques are frequently employed to increase the abundance of low-prevalence microorganisms before isolation, improving the detection of species that might otherwise remain undetected. Unlike sequencing-based approaches, culture methods allow researchers to obtain living microorganisms, making it possible to investigate their biological behaviour, pathogenicity, metabolic functions, and responses to therapeutic agents. These cultured isolates are also essential for developing probiotics, studying antimicrobial resistance, and performing experimental infection models. Despite these advantages, conventional culture methods have significant limitations. A large proportion of gut microorganisms cannot be cultured using standard laboratory techniques because many species require highly specialized environmental conditions, strict anaerobic atmospheres, unique nutritional requirements, or interactions with other microorganisms for growth. Consequently, traditional culture methods tend to underestimate microbial diversity and favour rapidly growing, metabolically adaptable species while overlooking slow-growing or obligate symbiotic microorganisms. Recent advances in culturomics have substantially expanded the capabilities of culture-based microbiology. Culturomics combines hundreds of optimized culture conditions with high-throughput microbial identification methods such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16S rRNA sequencing. This approach has enabled the isolation of numerous previously uncultivable bacterial species and has significantly broadened our understanding of gut microbial diversity. Although culturomics is more labor-intensive and resource-demanding than sequencing-based techniques, it remains an invaluable tool for recovering live microorganisms and validating findings obtained through molecular analyses.

4.5.2 Molecular Approaches

Molecular techniques have revolutionized gut microbiome research by allowing comprehensive analysis of microbial communities without the need for culture. These culture-independent methods provide a more complete representation

of microbial diversity because they can detect both culturable and unculturable microorganisms present within complex microbial ecosystems. Among these techniques, 16S ribosomal RNA (16S rRNA) gene sequencing remains the most widely used method for bacterial taxonomic profiling. The 16S rRNA gene contains highly conserved regions interspersed with variable regions that enable bacterial identification and phylogenetic classification. Sequencing these regions allows researchers to characterize microbial composition, estimate relative abundance, compare microbial communities, and evaluate changes associated with health or disease. Because of its relatively low cost and high throughput, 16S rRNA sequencing has become the standard method for large-scale microbiome studies.

However, this approach primarily provides taxonomic information and offers limited insight into microbial function or metabolic activity. To overcome these limitations, whole-metagenome sequencing (WMS) has emerged as a powerful alternative. Rather than sequencing a single genetic marker, metagenomic sequencing analyzes the entire collection of microbial DNA within a sample. This enables identification of microorganisms at species or strain level while simultaneously characterizing functional genes, metabolic pathways, virulence factors, antimicrobial resistance genes, and microbial interactions. Consequently, metagenomics provides both taxonomic and functional information, allowing researchers to better understand how microbial communities contribute to health and disease.

Continuous improvements in sequencing technologies have further enhanced microbiome research by increasing sequencing depth, read length, accuracy, and computational efficiency. Modern platforms now permit strain-level identification, detection of low-abundance microorganisms, and improved characterization of complex microbial communities. Integrating multiple molecular approaches including 16S rRNA sequencing, whole-metagenome sequencing, metatranscriptomics, metaproteomics, and metabolomics provides complementary taxonomic and functional information. Such integrated analyses have become essential for investigating microbial dysbiosis, metabolic disorders, inflammatory diseases, and complex host–microbe interactions.

4.5.3 Bioinformatics and Data Analysis

The enormous volume of data generated by modern sequencing technologies requires sophisticated bioinformatics tools for accurate processing, analysis, and interpretation. Bioinformatics has therefore become an indispensable component of microbiome research, enabling researchers to transform raw sequencing data into biologically meaningful information. The analytical workflow typically begins with quality assessment and filtering of raw sequencing reads, followed by sequence alignment, assembly, and removal of sequencing artifacts. These processed sequences are then compared with curated microbial databases to assign taxonomic identities and estimate microbial abundance within each sample. Functional annotation tools subsequently identify microbial genes and predict metabolic pathways, enzyme activities, antimicrobial resistance determinants, and other biological functions, providing insight into the metabolic capabilities of microbial communities. Advanced statistical methods are used to compare microbial communities between healthy and diseased individuals, identify differentially abundant taxa, evaluate microbial diversity, and detect patterns of dysbiosis associated with specific diseases. These analyses help identify microbial biomarkers that may serve as diagnostic indicators or therapeutic targets. More recently, bioinformatics has evolved beyond taxonomic analysis through the integration of multi-omics datasets, including metagenomics, metatranscriptomics, metabolomics, proteomics, and host transcriptomics.

Combining these complementary datasets enables researchers to examine microbial gene expression, metabolite production, protein synthesis, and host responses simultaneously, providing a comprehensive systems-level understanding of host–microbiome interactions. Artificial intelligence (AI) and machine learning algorithms have further expanded the analytical capabilities of microbiome research. These computational approaches can analyze highly complex datasets, identify previously unrecognized microbial patterns, predict disease risk, discover novel microbial biomarkers, and support the development of personalized microbiome-based

diagnostics and therapeutic strategies. As computational methods continue to advance, bioinformatics will play an increasingly important role in precision medicine by enabling detailed characterization of microbial diversity, temporal changes, functional activity, and their relationships with human physiology and disease.

4.6 METHODS OF STUDYING THE GUT MICROBIOME

Advances in microbiome research have been driven by the development of increasingly sophisticated techniques for identifying, characterizing, and analysing gut microorganisms. Early investigations relied primarily on culture-based microbiology, but these methods were limited because many intestinal microorganisms cannot be grown under standard laboratory conditions. The introduction of molecular sequencing technologies and bioinformatics has transformed the field by enabling comprehensive analysis of microbial diversity, functional capacity, and host–microbe interactions. Today, microbiome research typically combines traditional microbiology, next-generation sequencing, and computational analysis to provide a detailed understanding of microbial communities in both health and disease.

4.6.1 Culture-Based Techniques

Culture-based microbiological techniques formed the foundation of early gut microbiome research and continue to play an important role in microbiology laboratories. These methods involve growing microorganisms under carefully controlled laboratory conditions using aerobic or anaerobic culture systems together with selective and differential culture media to isolate individual bacterial species. Once isolated, microorganisms can be identified using colony morphology, Gram staining, biochemical assays, and phenotypic characterization. These techniques provide valuable information regarding microbial physiology, metabolism, antimicrobial susceptibility, and interactions with the host. Enrichment culture methods are frequently used to increase the recovery of microorganisms present in low abundance. By modifying growth conditions or supplying specific nutrients, these methods improve the isolation of microorganisms that might otherwise remain undetected. Unlike molecular techniques, culture-based approaches produce living microbial isolates that can be further investigated for pathogenicity, metabolic activity, probiotic potential, and antibiotic resistance. Despite their advantages, conventional culture techniques have important limitations. A large proportion of gut microorganisms are extremely difficult or impossible to cultivate using routine laboratory methods because they require highly specialized environmental conditions, strict anaerobic atmospheres, unique nutritional requirements, or interactions with neighbouring microorganisms for survival.

Consequently, traditional culture methods tend to favour rapidly growing and metabolically versatile bacteria while underrepresenting slow-growing or obligate symbiotic species, leading to an incomplete picture of gut microbial diversity. Recent developments in culturomics have significantly improved the capabilities of culture-based microbiology. Culturomics combines hundreds of optimized culture conditions with advanced identification techniques such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16S rRNA gene sequencing. This high-throughput approach has enabled the isolation of numerous previously uncultivable microorganisms, substantially expanding our knowledge of gut microbial diversity and function. Although culturomics is more labour-intensive and resource-demanding than sequencing-based approaches, it remains an invaluable method for obtaining live microbial isolates for experimental and clinical research.

4.6.2 Molecular Approaches

Molecular approaches have revolutionized gut microbiome research by enabling comprehensive analysis of microbial communities without the need for microbial culture. These culture-independent techniques detect both culturable and unculturable microorganisms, providing a more complete and accurate representation of the gut microbial ecosystem. Among the available molecular methods, 16S ribosomal RNA (16S rRNA) gene sequencing remains one of the most widely used techniques for microbial community profiling. The bacterial 16S rRNA gene contains highly conserved regions interspersed with hypervariable regions that allow taxonomic identification and phylogenetic classification of microorganisms. Sequencing these regions

enables researchers to identify bacterial genera and species, determine their relative abundance, and compare microbial communities across healthy and diseased individuals. Owing to its relatively low cost and high throughput, 16S rRNA sequencing has become the standard approach for large-scale microbiome studies. However, because it targets only a single genetic marker, it provides limited information regarding microbial functions, metabolic activities, and strain-level diversity.

To overcome these limitations, whole-metagenome sequencing (WMS) has emerged as a powerful alternative. Instead of analysing a single gene, metagenomic sequencing examines the complete microbial DNA present in a sample, allowing simultaneous identification of bacteria, archaea, fungi, viruses, and other microorganisms. More importantly, it enables characterization of microbial metabolic pathways, virulence factors, antimicrobial resistance genes, and functional interactions within complex microbial ecosystems. This comprehensive approach provides both taxonomic and functional information, offering deeper insights into the biological roles of gut microorganisms. Continuous improvements in next-generation sequencing technologies have further enhanced microbiome research by increasing sequencing accuracy, read length, throughput, and analytical resolution.

Modern sequencing platforms now permit strain-level identification and improved characterization of low-abundance microbial populations that were previously difficult to detect. Increasingly, researchers integrate multiple molecular approaches, including 16S rRNA sequencing, whole-metagenome sequencing, metatranscriptomics, metaproteomics, and metabolomics to obtain complementary information on microbial composition, gene expression, metabolic activity, and host interactions. Such integrated analyses have become essential for understanding microbial dysbiosis and its contribution to metabolic diseases, inflammatory disorders, and other complex human conditions.

4.6.3 Bioinformatics and Data Analysis

The enormous amount of information generated by high-throughput sequencing technologies requires advanced computational methods for accurate processing, interpretation, and visualization. Consequently, bioinformatics has become an indispensable component of modern microbiome research, enabling scientists to transform raw sequencing data into biologically meaningful information. Bioinformatics pipelines begin with quality assessment and filtering of raw sequencing reads, followed by sequence alignment, assembly, and removal of sequencing errors or contaminants. The processed sequences are then compared with reference databases to identify microbial taxa and determine their relative abundance within a sample.

Functional annotation tools further analyse microbial genes to predict enzyme activities, metabolic pathways, antimicrobial resistance determinants, and other biological functions, providing valuable insight into the functional capabilities of microbial communities. Statistical and computational methods are subsequently applied to compare microbial communities across different populations or disease conditions. Differential abundance analysis identifies microorganisms that are significantly enriched or depleted, while diversity indices evaluate changes in microbial richness and ecological balance. These analyses help detect microbial signatures associated with dysbiosis and various disease states, facilitating the discovery of potential diagnostic biomarkers and therapeutic targets. More recently, bioinformatics has evolved through the integration of multi-omics datasets, including metagenomics, transcriptomics, proteomics, and metabolomics. These complementary datasets enable simultaneous investigation of microbial genes, gene expression, proteins, metabolites, and host responses, providing a systems-level understanding of host–microbiome interactions.

In addition, artificial intelligence (AI) and machine learning algorithms have become increasingly important for analysing complex microbiome datasets. These computational techniques improve predictive modelling, identify disease-associated microbial biomarkers, and support the development of personalized microbiome-based diagnostics and therapeutic strategies. Collectively, these advanced bioinformatics approaches provide comprehensive insights into microbial diversity, temporal dynamics, functional activity, and their

relationships with physiological and pathological processes, thereby accelerating microbiome research and advancing precision medicine.

4.7 DYSBIOSIS AND DISEASE ASSOCIATIONS

Dysbiosis denotes a state of imbalance in the gut microbiome, marked by alterations in the composition, diversity, and functional capability of microbial communities that deviate from a healthy stabilit. This imbalance is commonly characterised by diminished microbial diversity, a decline in beneficial microorganisms, and a simultaneous expansion of opportunistic or pathogenic populations. Furthermore, beyond compositional shifts, dysbiosis includes functional disruptions, comprising metabolic functioning, impaired SCFAs production, and dysregulation of microbial signalling pathways. These alterations compromise host physiological processes via compromising intestinal barrier stability, modulating immune responses, and disrupting microbial homeostasi. Therefore, dysbiosis has gained recognition as a critical factor in the pathogenesis of various diseases, including inflammatory, metabolic, and gastrointestinal diseases.

4.7.1 Gastrointestinal disorders

Gut microbiome dysbiosis has emerged as a key contributor to gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer. Dysbiosis contributes to IBD via disruption of microbial equilibrium, characterised by reduced beneficial bacteria and expansion of pro-inflammatory species, which tend to immune dysregulation and chronic intestinal inflammation. Functional disruption, such as altered microbial profiles and impaired barrier stability, exacerbates mucosal immune activation, driving disease progression. In IBS, microbial changes contribute to abnormal intestinal motility, visceral hypersensitivity, and gut-brain axis signalling, manifesting as functional gut symptoms in the absence of unconcealed inflammation. Dysbiotic alteration, including reduced microbial diversity and shift in fermentation pathways, alters gas production and mucosal signalling, thereby contributing to symptom severit. In colorectal cancer, dysbiosis enhances tumorigenesis via multiple mechanisms, including production of carcinogenic metabolites, induction of chronic inflammation, and activation of oncogenic signalling pathways. Specific microbial species can alter host immune responses and metabolic pathways, thereby smoothing tumour initiation and progression. Alterations in microbiome are increasingly recognised for clinical implications, contributing potential for diagnostic biomarkers and microbiome-targeted therapies focused on restoring microbial balance and limiting disease progression.

4.7.2 Metabolic disorders

Gut microbiome dysbiosis plays a central role in metabolic disorders, including obesity, type 2 diabetes, and metabolic syndrome. In obesity, microbial alteration promotes energy yield from diet, modulating lipid metabolism, and promoting chronic low-grade inflammation through endotoxin-mediated immune activation. Dysbiosis-associated alteration in SCFAs production and bile acid metabolism affects adiposity and metabolic regulation. In type 2 diabetes, alterations in the gut microbiota are associated with impaired metabolism and insulin resistance, mediated by inflammatory pathways that affect gut permeability and shift microbial metabolites such as SCFAs and branched-chain amino acids. These microbial dysbioses alter metabolic signalling, creating a disturbance that accelerates the progression of disease. Moreover, dysbiosis contributes significantly to metabolic syndrome by driving chronic systemic inflammation, oxidative stress, and metabolic dysregulation, thereby establishing a link between obesity, insulin resistance, and cardiovascular factors. The dynamic relationship between microbial composition and host metabolic pathways highlights the significance of the gut microbiome in maintaining metabolic stability. Clinically, this evidence supports microbiome-focused interventions, including probiotics, prebiotics, and dietary variation, as promising approaches for the prevention and treatment of metabolic disorders.

4.7.3 Neurological and psychiatric disorders

Dysbiosis in the gut microbiome contributes to neurological and psychiatric disease via disrupting host-microbe interactions. This occurs via the microbiota-gut-brain axis, which signifies a bidirectional communication pathway

associating the gastrointestinal tract and the central nervous system through neural, endocrine, and immune pathways. This axis empowers gut microbiota to influence brain function via the production of neurotransmitters, modulating the vagus nerve, and regulating systemic immune responses. Changes in gut microbial community are linked to depression and anxiety, where dysbiosis underwrites the neurotransmission imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and heightened neuroinflammation. Likewise, in autism spectrum disorders, microbial discrepancies are associated with altered metabolite profiles, heightened immune activation, and disruption in neurodevelopmental signalling pathways. In neurodegenerative diseases, particularly Parkinson's disease, gut microbiota modifications are concerned with α-synuclein aggregation, increased intestinal permeability, and chronic inflammation, which may aid neurodegeneration via the gut-brain axis. Underlying these associations are microbial-derived products such as SCFAs and host signalling molecules, and pro-inflammatory cytokines that affect neuronal function and brain equilibrium. Mutually, these findings emphasise the critical role of gut microbiome in shaping neurological health and highlight its potential as a therapeutic target across neuropsychiatric and neurodegenerative diseases.

4.7.4 Immune and autoimmune diseases

Gut microbiome dysbiosis progressively plays a central role in autoimmune disease by disrupting the immune system and autoimmunity. The gut microbiota maintains immune homeostasis through dynamic host-microbe communication, influencing immune cell proliferation, cytokine signalling, and mucosal barrier maintenance. Microbial metabolites, mainly SCFAs, regulate anti-inflammatory pathways and enhance immune tolerance, whereas dysbiosis disrupts these protective mechanisms, leading to heightened pro-inflammatory activity. One hallmark of dysbiosis is the disruption of the homeostasis between Treg and pro-inflammatory Th17 cells, which promotes inappropriate immune activation and sustains chronic inflammatory responses. Additionally, shifts in microbial population affect B-cell differentiation and antibody production, further leading to autoimmune pathogenesis. These immunological disruptions are concerned with diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, where discrete microbial signatures have been identified. The clinical significance of these discoveries underscores the use of microbiome profiles as diagnostic biomarkers and therapeutic targets. Emerging microbiome-based interventions include probiotics, prebiotics, and faecal microbiota transplantation, which focus on restoring microbial balance and modulating immune responses, offering promising strategies for managing autoimmune diseases.

4.8 THERAPEUTIC MODULATION OF THE GUT MICROBIOME

A. Probiotics: Probiotics are defined as live microorganisms that, when administered in sufficient quantity, promote health benefits to the host through modulation of the gut microbiome. They act by re-establishing microbial homeostasis, preventing colonisation by pathogens, and promoting intestinal barrier functioning. These microbes produce SCFAs that strengthen the gut lining and help regulate metabolism. Additionally, probiotics influence immune regulation by manipulating cytokine production, heightening Treg cell activity, and decreasing pro-inflammatory signalling. Clinically, probiotics are highlighted as important modulators of gut health and management of gastrointestinal disorders, including IBD and IBS, and show promise in metabolic and immune-mediated conditions. Although probiotics are tempered by key limitations, including strain-specific efficacy, variability in clinical outcomes, and concerns regarding safety in immune-compromised hosts. Emerging therapeutics emphasise next-generation probiotics and personalised microbiome-based interventions, which are marked to specific Dysbiotic profiles and improve therapeutic precision. This progress underscores the emerging role of probiotics in microbiome modulation and disease management.
B. Prebiotics: Prebiotics are selectively fermented, non-digestible dietary components that confer health benefits through shifting the composition and activity of the gut microbiome. They primarily function to promote the growth and activity of beneficial bacteria, including *Bifidobacterium* and *Lactobacillus,* thereby enhancing a symbiotic microbial balance. Through microbial fermentation, non-digestible compounds are converted into SCFAs such as acetate, propionate, and butyrate, which augment

intestinal barrier stability, regulate immune responses, and affect host metabolism. Clinically, prebiotics enhance gastrointestinal health, lessening symptoms of disorders including IBS, and metabolic conditions like obesity and type 2 diabetes. Furthermore, the immunomodulatory effect of prebiotics underwrites the management of both inflammatory and immune-related disease. Nevertheless, limitations remain, including inter-individual variability in response due to differences in baseline microbiota composition, difficulty in determining optimal dosages, and limited understanding of long-term effects. Current research emphasised personalised nutritional interventions together with innovative prebiotics formulations to refine microbiome modulation and therapeutic efficacy.

C. Synbiotics: Synbiotics are represented as a synergistic combination of probiotics and prebiotics designed to optimise gut health. Synbiotics employ their effect via complementary mechanisms, where prebiotics enhance the growth of administered probiotic strains, thereby improving colonisation efficiency and microbial stability. This synergistic collaboration stimulates favourable modulation of gut microbiota composition and improves production of beneficial metabolites such as SCFAs, which sustain intestinal barrier stability, immune regulation, and metabolic equilibrium. Clinically, Synbiotics have demonstrated potential in improving gastrointestinal health, supervising disorders including IBS, and modulating metabolic diseases, including obesity and type 2 diabetes. In addition, emerging research suggests their role in immune modulation and regulation of the gut-brain axis, affecting neuro-immune and neuroendocrine pathways. Conversely, limitations include erraticism in Synbiotics formulations, strain-specific efficacy, and a lack of standardised clinical protocols, which leads to unreliable results across studies. Current investigations emphasise the refinement of symbiotic formulations alongside the development of personalised microbiome-based therapies to improve therapeutic precision and efficacy.

D. Faecal microbiota transplantation (FMT): Faecal microbial transplantation (FMT) is a therapeutic method that involves the transfer of processed faecal material from a healthy individual to a patient's gut to re-establish microbial diversity. FMT acts by restoring microbial population and ecological stability within the gut, thereby altering dysbiosis and restoring functional homeostasis. It strengthens colonisation resistance by facilitating competitive exclusion of pathogenic organisms, while simultaneously supporting the restoration of beneficial microbial diversity and their metabolic functions. FMT involves several steps, including donor selection, processing of faecal material, and the administering process. The healthy individual undergoes several screenings, including serological testing and faecal pathogen determination, to minimise the risk of infection. After the complete screening, the faecal sample undergoes processing: 50g of faeces is diluted with normal saline, blended into a solution, filtered through 5-layer sterile gauze, and stored at -80°C. FMT utilises numerous routes of administration, comprising colonoscopy, oral capsule, nasogastric, and upper endoscopy. Clinically, FMT is recognised as a highly effective therapy for recurrent Clostridioides difficile infection, with consistently high success rates in restoring gut microbiota composition. Beyond its primary indication, FMT has an established role in recurrent *Clostridioides difficile* infection, and emerging evidence supports the use of FMT in gastrointestinal disorders such as inflammatory bowel disease and chronic constipation, besides in metabolic and systemic conditions. Despite its therapeutic potential, faecal microbiota transplantation faces several challenges, including risk of pathogen transmission, variability in donor microbiota population, and the need for rigorous donor screening protocols. Regulatory uncertainties and unreliable clinical results further bound its widespread implementation. Future research emphasises the establishment of standardised protocols, defined microbial consortia, and next-generation microbiome-based therapies to make treatment safer, reproducible, and clinically efficacious.

E. Diet-based interventions: Diet-based interventions, mainly structured dietary patterns such as the Mediterranean diet, represent a key strategy for modulating the gut microbiome and improving host health. Which influences gut microbiome diversity by promoting the abundance of beneficial microorganisms and supporting overall microbial diversity through the intake of a fibre-rich, plant-based diet. Fermentation of dietary fibres via gut microbiota generates SCFAs, notably butyrate, which maintain intestinal barrier integrity, regulate

immune responses, and contribute to metabolic equilibrium. Clinically, interaction between diet and gut microbiome plays a critical role in managing metabolic disorders, cardiovascular disease, and type 2 diabetes via enlightening lipid metabolism, diminishing systemic inflammation, and enhancing insulin sensitivity. Emerging strategies, including personalised nutrition and artificial intelligence-derived dietary mediations, leverage individual microbiome profiles to optimise dietary recommendations and therapeutic outcomes. However, limitations persist, including marker inter-individual inconsistency in microbiome responses, difficulties in sustaining long-term dietary adherence, and incomplete consideration of sustained microbiome alteration and clinical effects. These dynamics highlight the need for further research to enhance diet-based interventions for precision microbiome modulation.

F. Emerging therapies: Emerging microbiome-based strategies incorporate innovative strategies aimed at modulating gut microbial composition and function for therapeutic benefit. Postbiotics, well-defined as non-viable microbial cells, components, or metabolites that confer health benefits, represent a key advancement in this pitch. These bioactive compounds act through immune modulation, anti-inflammatory mechanisms, and regulation of host metabolic pathways, thereby influencing systemic physiology without the risks associated with live microorganisms. Advanced therapeutic interventions include engineered postbiotics with targeted functionalities, microbiome-directed drug delivery systems, and nanoparticle platforms designed to enhance stability, bioavailability, and site-specific delivery. Remarkably, colon-targeted, nanoparticle-mediated delivery of postbiotics has established therapeutic potential in modulating the gut-bone axis and alleviating osteoporosis. These strategies hold therapeutic potential in managing chronic disease, including metabolic disorders, inflammatory conditions, and immune-mediated pathologies. Nevertheless, barriers such as regulatory uncertainty, safety assessment, production scalability, and the need for rigorous clinical validation limit widespread application. Future directions highlight meticulousness in microbiome therapeutics, the integration of multi-omics technologies, and the development of standardised frameworks to optimise clinical transformation and therapeutic efficacy.

4.9 CHALLENGES AND LIMITATIONS

Gut microbiome research is inherently complex due to the vigorous and multifactorial nature of host-microbiome interactions. A major encounter arises from substantial inter-individual and population-level erraticism in microbiome composition, predisposed by factors such as genetics, diet, geography, and lifestyle, which complicates reproducibility and limits generalizability across cohorts. Establishing interconnection remains a perilous hurdle, as most microbiome-disease associations are derived from observational studies that cannot distinguish cause from effect, while preclinical models often fail to replicate human physiology and microbial complexity. Progress in microbiome research is hindered by methodological discrepancies, including inconsistencies in sample collection, storage conditions, sequencing platforms, and bioinformatics pipelines, which reduce data comparability and complicate interpretation across studies. Additionally, longitudinal studies encounter challenges related to chronological variability, participant retention, and the integration of high-dimensional datasets, particularly when incorporating multi-omics interventions such as metagenomics, metabolomics, and transcriptomics. Ethical and regulatory concerns also pose significant barriers, particularly regarding direct-to-consumer microbiome testing, data privacy, and the clinical translation of microbiome-based therapies. Likewise, translation of microbiome research into clinical practice remains limited by inadequate standardisation, the absence of validated biomarkers, and imperfect consideration of host-microbiome interactions in disease pathogenesis. Taken together, these challenges highlight the need for standardised methodologies, robust frameworks for pivotal interpretation, and interdisciplinary strategies to advance the field toward clinically actionable outcomes.

4.10 FUTURE PERSPECTIVES

The gut microbiome is expected to play a transformative role in future healthcare through advances in precision medicine and integrative biomedical technologies. Personalised and precision medicine approaches are progressively leveraging microbiome profiling to develop

individualised diagnostics and targeted therapies, mainly in multifarious diseases such as inflammatory bowel disease (IBD), where microbial signatures can inform clinical decision-making. Microbiome-based therapies are proceeding through the expansion of engineered microbes and targeted microbial interventions intended to re-establish specific functional discrepancies and address disease-associated dysbiosis. The combination of multi-omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, has considerably innovated the consideration of host-microbe interactions by providing a comprehensive perception into microbial function, metabolic pathways, and regulatory networks.

These approaches enable a systems-level understanding of disease mechanisms and promote the identification of novel biomarkers and therapeutic targets. Artificial intelligence and machine learning have advanced microbiome research by supporting high-dimensional data analysis, predictive modelling, and the improvement of clinical decision-support tools. Evolving fields such as nutrigenomics underline the interaction between diet, host genetics, and microbiome diversity, proposing novel pathways for personalised diet-based interventions. Furthermore, synthetic biology is driving innovation in next-generation microbiome therapeutics, including engineered microbial consortia with heightened functional capabilities. Collectively, these encroachments present momentous opportunities to decode microbiome research into precision healthcare solutions, with the potential to improve disease prevention, diagnosis, and cure on a comprehensive scale.

4.11 CONCLUSION

The gut microbiome functions as a central regulator of human homeostasis, coordinating metabolic, immunological, and neuroendocrine functions. This chapter underscores that a balanced and diverse gut ecosystem is necessary to uphold intestinal integrity, modulate immune responses, and support systemic metabolic processes through the production of bioactive metabolites, including SCFAs and vitamins. Dysbiosis or disruption in microbial composition is consistently associated with the development of disorders, including gastrointestinal, metabolic, neurological, and autoimmune diseases, thereby reinforcing the microbiome's clinical significance. Moreover, the complex interplay among host factors, environmental influences, and microbial communities emphasises the complexity of microbiome dynamics and the hurdles in translating research findings into standardised clinical applications. Therapeutic interventions, including probiotics, prebiotics, Synbiotics, faecal microbiota transplantation, and diet-based interventions, show assurance in re-establishing microbial homeostasis; however, their efficiency is constrained by inter-individual variability and methodological limitations. Advances in multi-omics technologies, artificial intelligence, and precision medicine are anticipated to improve mechanistic considerations and facilitate the development of targeted, personalised microbiome-based interventions. Co-operatively, the gut microbiome established an important frontier in biomedical research, with momentous implications for future diagnostics, disease prevention, and therapeutic innovations.

REFERENCES

1. Marano G, Mazza M, Lisci FM, Ciliberto M, Traversi G, Kotzalidis GD, et al. The microbiota–gut–brain axis: psychoneuroimmunological insights. Nutrients. 2023;15(6):1496. doi:10.3390/nu15061496.
2. Berg G, Rybakova D, Fischer D, Cernava T, Vergès MCC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8(1):103. doi:10.1186/s40168-020-00875-0.
3. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3(1):31. doi:10.1186/s40168-015-0094-5.
4. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. doi:10.1126/science.1110591.
5. Huang X, Fan X, Ying J, Chen S. Emerging trends and research foci in gastrointestinal microbiome. J Transl Med. 2019;17(1):67. doi:10.1186/s12967-019-1810-x.
6. Costea PI, Hildebrand F, Arumugam M, Bäckhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol. 2018;3(1):8–16. doi:10.1038/s41564-017-0072-8.
7. Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC

Microbiol. 2016;16(1):90. doi:10.1186/s12866-016-0708-5.
8. Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, Davis RW. Microbes on the human vaginal epithelium. Proc Natl Acad Sci U S A. 2005;102(22):7952–7957.
9. Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Differences in the composition of vaginal microbial communities found in healthy Caucasian and Black women. ISME J. 2007;1(2):121–133.
10. Grölund M, Lehtonen O, Eerola E, Kero P. Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr. 1999;28(1):19–25.
11. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17(5):690–703.
12. Penders J, Vink C, Driessen C, London N, Thijs C, Stobberingh EE. Quantification of Bifidobacterium spp., Escherichia coli, and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol Lett. 2005;243(1):141–147.
13. Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 2011;17(6):478–482.
14. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4578–4585.
15. Korpela K, Kallio S, Salonen A, Hero M, Kukkonen AK, Miettinen PJ, et al. Gut microbiota develop towards an adult profile in a sex-specific manner during puberty. Sci Rep. 2021;11(1):23297.
16. Schoultz I, Claesson MJ, Dominguez-Bello MG, Fåk Hållenius F, Konturek P, Korpela K, et al. Gut microbiota development across the lifespan: disease links and health-promoting interventions. J Intern Med. 2025;297(6):560–583.
17. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14.
18. Ghosh TS, Shanahan F, O'Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol. 2022;19(9):565–584.
19. Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol Immunol. 2023;20(4):341–350. doi:10.1038/s41423-023-00987-1.
20. Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024;24(8):577–595.
21. Münte E, Hartmann P. The role of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and other metabolic diseases. Biomolecules. 2025;15(4):469.
22. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev. 1997;6(Suppl 1):S43–S45. doi:10.1097/00008469-199703001-00009.
23. LeBlanc JG, Milani C, De Giori GS, Sesma F, Van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160–168.
24. Luo W, Li R, Pan C, Luo C. Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy. Front Immunol. 2025;16:1710880.
25. Ricci JE. Tumor-induced metabolic immunosuppression: mechanisms and therapeutic targets. Cell Rep. 2025;44(1):115206. doi:10.1016/j.celrep.2024.115206.
26. Kim CH. Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 2021;18(5):1161–1171.
27. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24.
28. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
29. Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236–247. doi:10.1038/s41579-022-00805-x.
30. D'Alessandro G, Antonangeli F, Marrocco F, Porzia A, Lauro C, Santoni A, et al. Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice. Eur J Immunol. 2020;50(5):705–711. doi:10.1002/eji.201948354.
31. Yurtseven B, Aydemir E, Ayaz F. The role of intestinal microbiota and immune system interactions in autoimmune diseases. ImmunoTargets Ther. 2025;14:1347–1372. doi:10.2147/ITT.S569016.
32. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol. 2015;15(12):731–744. doi:10.1038/nri3920.

33. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506. doi:10.1038/s41422-020-0332-7.
34. Macpherson AJ, Pachnis V, Prinz M. Boundaries and integration between microbiota, the nervous system, and immunity. Immunity. 2023;56(8):1712–1726. doi:10.1016/j.immuni.2023.07.011.
35. Till JM, Brock OD, Ahern PP. Striking a balance: how the gut microbiome shapes the fate of intestinal CD4+ T cells. Discov Immunol. 2026;5(1):kyaf020. doi:10.1093/discim/kyaf020.
36. Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker HC, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe. 2014;15(4):413–423. doi:10.1016/j.chom.2014.03.006.
37. Verma R, Lee C, Jeun EJ, Yi J, Kim KS, Ghosh A, et al. Cell surface polysaccharides of Bifidobacterium bifidum induce the generation of Foxp3+ regulatory T cells. Sci Immunol. 2018;3(28):eaat6975. doi:10.1126/sciimmunol.aat6975.
38. Mesenchymal stem cells infusion and renal revascularization in atherosclerotic renal artery stenosis: new modalities in therapeutic approach. J Community Med Public Health. 2024;8(2).
39. Liu XF, Shao JH, Liao YT, Wang LN, Jia Y, Dong PJ, et al. Regulation of short-chain fatty acids in the immune system. Front Immunol. 2023;14:1186892.
40. Yoo J, Groer M, Dutra S, Sarkar A, McSkimming D. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. doi:10.3390/microorganisms8101587.
41. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability: a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14(1):189. doi:10.1186/s12876-014-0189-7.
42. Snelson M, Vanuytsel T, Marques FZ. Breaking the barrier: the role of gut epithelial permeability in the pathogenesis of hypertension. Curr Hypertens Rep. 2024;26(9):369–380. doi:10.1007/s11906-024-01307-2.
43. Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. Front Physiol. 2024;15:1380713. doi:10.3389/fphys.2024.1380713.
44. Hansson GC. Mucus and mucins in diseases of the intestinal and respiratory tracts. J Intern Med. 2019;285(5):479–490. doi:10.1111/joim.12910.
45. Luis AS, Hansson GC. Intestinal mucus and their glycans: a habitat for thriving microbiota. Cell Host Microbe. 2023;31(7):1087–1100. doi:10.1016/j.chom.2023.05.026.
46. Gutierrez A, Pucket B, Engevik MA. Bifidobacterium and the intestinal mucus layer. Microbiome Res Rep. 2023;2(4). doi:10.20517/mrr.2023.37.
47. Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut. 2020;69(12):2232–2243. doi:10.1136/gutjnl-2020-322260.
48. Matar A, Damianos JA, Jencks KJ, Camilleri M. Intestinal barrier impairment, preservation, and repair: an update. Nutrients. 2024;16(20):3494. doi:10.3390/nu16203494.
49. Shen H, Wang SY, Zhao YY, Zhou JL, Zhao J, Zhu WK. Brain–gut–microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Front Microbiol. 2026;17:1768891. doi:10.3389/fmicb.2026.1768891.
50. Kim YS, Woo SY, Ha E, Ahn SH, Kim E, Kim SI, et al. Role of gut microbiota in psychiatric disorders: from mechanistic insights to therapeutic strategies. J Korean Med Sci. 2026;41(8):e78. doi:10.3346/jkms.2026.41.e78.
51. Bautista J, Hidalgo-Tinoco C, Di Capua Delgado M, Viteri-Recalde J, Guerra-Guerrero A, López-Cortés A. The gut–brain–circadian axis in anxiety and depression: a critical review. Front Psychiatry. 2025;16:1697200. doi:10.3389/fpsyt.2025.1697200.
52. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820.
53. Duranti S, Ruiz L, Lugli GA, Tames H, Milani C, Mancabelli L, et al. Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA. Sci Rep. 2020;10(1):14112. doi:10.1038/s41598-020-70986-z.
54. Ibeas-Pérez MV, Agüí-Ruiz B, Arias-Sánchez S, Martín-Monzón I. Mediterranean diet and gut microbiota: impact on memory and other cognitive functions: a systematic review. Front Mol Neurosci. 2026;19:1749308. doi:10.3389/fnmol.2026.1749308.
55. Özçam M, Lynch SV. The gut–airway microbiome axis in health and respiratory diseases. Nat Rev Microbiol. 2024;22(8):492–506. doi:10.1038/s41579-024-01048-8.
56. Liu J, Hong W, Sun Z, Zhang S, Xue C, Dong N. The gut–lung axis: effects and mechanisms of gut microbiota on pulmonary diseases. Front Immunol. 2026;16:1693964. doi:10.3389/fimmu.2025.1693964.
57. Yu X, Yu X, Wang Y, Guo X, Wang C, Wang F. Respiratory diseases and the gut microbiota: an updated review. Front Cell Infect Microbiol. 2025;15:1629005. doi:10.3389/fcimb.2025.1629005.

58. Yang Z, Mao W, Wang J, Yin L. The gut–lung axis in asthma: microbiota-driven mechanisms and therapeutic perspectives. Front Microbiol. 2025;16:1680521. doi:10.3389/fmicb.2025.1680521.
59. Deepika, Alsharari ZD, Ahmad MF, Singh J, Yadav M, Kumari A, et al. Gut–lung axis, probiotics, and prebiotics: insights on dysbiosis, mechanism, and prevention of lung cancer. Front Nutr. 2025;12:1624803. doi:10.3389/fnut.2025.1624803.
60. Wang Z, Yu J, Liu Y, Gong J, Hu Z, Liu Z. Role of the microbiota–gut–lung axis in the pathogenesis of pulmonary disease in children and novel therapeutic strategies. Front Immunol. 2025;16:1636876. doi:10.3389/fimmu.2025.1636876.
61. Stricker S, Hain T, Chao CM, Rudloff S. Respiratory and intestinal microbiota in pediatric lung diseases: current evidence of the gut–lung axis. Int J Mol Sci. 2022;23(12):6791. doi:10.3390/ijms23126791.
62. Cosimato I, Brescia A, Franci G, Casolaro V, Folliero V. Emerging therapeutic approaches for modulating the intestinal microbiota. Pharmaceutics. 2026;18(2):197. doi:10.3390/pharmaceutics18020197.
63. Bautista J, Echeverría CE, Maldonado-Noboa I, Ojeda-Mosquera S, Hidalgo-Tinoco C, López-Cortés A. The human microbiome in clinical translation: from bench to bedside. Front Microbiol. 2025;16:1632435. doi:10.3389/fmicb.2025.1632435.
64. Han Y, Wang Z, Xie J, Yang G, Su M, Wang S, et al. Host–gut microbiota interactions in health and disease: mechanisms and intervention strategies. Front Microbiol. 2026;17:1785607.
65. Cecan AD, Cătoi AF, But A, Morar II. Nutritional status in obesity: a comprehensive narrative review of dysbiosis, micronutrient deficiencies and the effects of probiotics/synbiotics. Medicina (Kaunas). 2026;62(3):458.
66. Borrego-Ruiz A, Borrego JJ. The gut microbiome in human obesity: a comprehensive review. Biomedicines. 2025;13(9):2173. doi:10.3390/biomedicines13092173.
67. Masi D, Watanabe M, Clément K. Gut microbiome and obesity care: bridging dietary, surgical, and pharmacological interventions. Cell Rep Med. 2026;7(2):102573. doi:10.1016/j.xcrm.2025.102573.
68. LeBlanc JG, Milani C, De Giori GS, Sesma F, Van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160–168.
69. Luo W, Li R, Pan C, Luo C. Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy. Front Immunol. 2025;16:1710880. doi:10.3389/fimmu.2025.1710880.
70. Ricci JE. Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets. Cell Rep. 2025;44(1):115206.
71. Kim CH. Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 2021;18(5):1161–1171.
72. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57(1):1–24.
73. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
74. Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236–247.
75. D'Alessandro G, Antonangeli F, Marrocco F, Porzia A, Lauro C, Santoni A, et al. Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice. Eur J Immunol. 2020;50(5):705–711. doi:10.1002/eji.201948354.
76. Yurtseven B, Aydemir E, Ayaz F. The role of intestinal microbiota and immune system interactions in autoimmune diseases. ImmunoTargets Ther. 2025;14:1347–1372. doi:10.2147/ITT.S569016.
77. Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol. 2015;15(12):731–744. doi:10.1038/nri3920.
78. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506.
79. Macpherson AJ, Pachnis V, Prinz M. Boundaries and integration between microbiota, the nervous system, and immunity. Immunity. 2023;56(8):1712–1726.
80. Till JM, Brock OD, Ahern PP. Striking a balance: how the gut microbiome shapes the fate of intestinal CD4+ T cells. Discov Immunol. 2026;5(1):kyaf020. doi:10.1093/discim/kyaf020.
81. Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker HC, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe. 2014;15(4):413–423.
82. Verma R, Lee C, Jeun EJ, Yi J, Kim KS, Ghosh A, et al. Cell surface polysaccharides of Bifidobacterium bifidum induce the generation of Foxp3+ regulatory T cells. Sci Immunol. 2018;3(28):eaat6975.

83. Mesenchymal stem cells infusion and renal revascularization in atherosclerotic renal artery stenosis: new modalities in therapeutic approach. J Community Med Public Health. 2024;8(2). doi:10.29011/2577-2228.100424.
84. Liu XF, Shao JH, Liao YT, Wang LN, Jia Y, Dong PJ, et al. Regulation of short-chain fatty acids in the immune system. Front Immunol. 2023;14:1186892.
85. Yoo J, Groer M, Dutra S, Sarkar A, McSkimming D. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. doi:10.3390/microorganisms8101587.
86. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability: a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.
87. Snelson M, Vanuytsel T, Marques FZ. Breaking the barrier: the role of gut epithelial permeability in the pathogenesis of hypertension. Curr Hypertens Rep. 2024;26(9):369–380. doi:10.1007/s11906-024-01307-2.
88. Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. Front Physiol. 2024;15:1380713.
89. Hansson GC. Mucus and mucins in diseases of the intestinal and respiratory tracts. J Intern Med. 2019;285(5):479–490. doi:10.1111/joim.12910.
90. Luis AS, Hansson GC. Intestinal mucus and their glycans: a habitat for thriving microbiota. Cell Host Microbe. 2023;31(7):1087–1100.